CSIMarket
 
Gilead Sciences Inc   (NASDAQ: GILD)
Other Ticker:  
 
 
Price: $95.5900 $0.11 0.115%
Day's High: $95.51 Week Perf: -4.07 %
Day's Low: $ 95.06 30 Day Perf: 6.35 %
Volume (M): 166 52 Wk High: $ 100.51
Volume (M$): $ 15,891 52 Wk Avg: $78.95
Open: $95.33 52 Wk Low: $62.07



 Market Capitalization (Millions $) 119,870
 Shares Outstanding (Millions) 1,254
 Employees 18,000
 Revenues (TTM) (Millions $) 28,299
 Net Income (TTM) (Millions $) 114
 Cash Flow (TTM) (Millions $) -669
 Capital Exp. (TTM) (Millions $) 591

Gilead Sciences Inc
Company Profile: Gilead Sciences, Inc.

Overview:
Gilead Sciences, Inc. is a leading biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics to improve the health and quality of life for patients with life-threatening diseases around the globe. Based in Foster City, California, the company has established itself as a pioneer in the field of antiviral and anti-infective therapies, with a strong focus on areas including HIV, hepatitis, and infectious diseases.

Key Products:
Gilead has an extensive portfolio of marketed products, many of which have become standard therapies in their respective categories. They include:

- Viread (tenofovir disoproxil fumarate): Used in combination with other antiretroviral agents for the treatment of HIV infection, both in the United States and internationally.

- Emtriva (emtricitabine): Another key antiretroviral medication approved for use in the treatment of HIV infection in adults; a fixed-dose combination with Viread is currently under development.

- AmBisome (liposomal amphotericin B): Indicated for the treatment of serious fungal infections and marketed in over 45 countries globally. Gilead collaborates with Fujisawa Healthcare, Inc. for its promotion in the U.S.

- Hepsera (adefovir dipivoxil): Prescribed for chronic hepatitis B treatment, marketed in both the U.S. and certain international markets, including Europe.

- Tamiflu (oseltamivir phosphate): An antiviral medication used for the prevention and treatment of influenza, marketed worldwide in collaboration with Roche.

- Vistide (cidofovir): Indicated for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients, marketed in the U.S. and through a partnership with Pfizer in various countries.

Commercial Operations:
Gilead operates robust U.S. and international sales teams, with marketing affiliates strategically positioned across Europe, Asia, and Australia. The company utilizes a comprehensive sales strategy involving direct engagement with healthcare providers, hospitals, and clinics to ensure broad access to its products.

Collaborative Relationships:
Gilead is committed to collaboration with various partners in the pharmaceutical industry to enhance its research and development capabilities. Key collaborations include:

- Archemix Corporation: Partnership involving a license for SELEX technology to discover aptamers.

- Chiron Corporation: Licensing agreement for small molecule therapeutics aimed at hepatitis C.

- GlaxoSmithKline: Exclusive rights granted for Hepseras commercialization in Asia and Latin America.

Recent Developments:
As of 2023, Gilead continues to expand its portfolio with ongoing research and development endeavors. The company has invested in next-generation antiviral therapies, including long-acting formulations for HIV, as well as treatments for emerging infectious diseases. Its commitment to innovation is evident in the continuous expansion and improvement of its product pipeline.

Conclusion:
Gilead Sciences, Inc. remains a key player in the biopharmaceutical landscape, with a focus on advancing healthcare solutions for patients with critical health needs. Through strategic collaborations and a commitment to research, Gilead aims to sustain its leadership in antiviral therapies and address unmet medical needs in infectious diseases.


   Company Address: 333 Lakeside Drive Foster City 94404 CA
   Company Phone Number: 574-3000   Stock Exchange / Ticker: NASDAQ GILD


Customers Net Income fell by GILD's Customers Net Profit Margin fell to

-34.03 %

1.62 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -4.55%    
BCRX        6.67% 
BIIB   -3.56%    
CHRS        0.86% 
EXEL   -2.64%    
HALO   -1.06%    
• View Complete Report
   



Business Update

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molec...

Published Tue, Dec 17 2024 2:40 PM UTC

Unlocking the Future of Drug Discovery: Gilead and Terray Therapeutics Forge a Multi-Target Collaborative PathwayIn a high-stakes pursuit of innovative healthcare solutions, Gilead Sciences, Inc. and Terray Therapeutics, Inc. have announced a strategic collaboration that aims to harness cutting-edge technology in the realm of drug discovery. This exciting partnership will f...

Business Update

New Horizons for Liver Health Gileads Seladelpar Wins CHMP Approval Amidst Robust Revenue Growth,

Published Fri, Dec 13 2024 1:24 PM UTC

Seladelpar Shines: Gilead Sciences Takes a Leap in Battling Primary Biliary Cholangitis In a significant stride for those battling liver diseases, Gilead Sciences, Inc. recently heralded a promising development: the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the use of seladelpar for treating...

Business Update

Gilead Sciences Innovating HIV Prevention with Lenacapavir Amid Mixed Financial Results in a Competitive Landscape,

Published Thu, Nov 28 2024 3:47 AM UTC

Gilead Sciences: A Competitive Edge in HIV Prevention Amidst Mixed Financial PerformanceIn a significant stride for HIV prevention, Gilead Sciences, Inc. (NASDAQ: GILD) recently announced the publication of the full results from its pivotal Phase 3 PURPOSE 2 trial in the New England Journal of Medicine (NEJM). This landmark study demonstrates the high efficacy of lenacapavi...

Business Update

Seladelpar Proves Effective in Lactate-Free Primary Biliary Cholangitis Treatment as Gilead Faces Revenue Chall...

Published Mon, Nov 18 2024 7:15 AM UTC

Gilead Sciences, Inc. (Nasdaq: GILD), a leader in biopharmaceutical innovation, has announced promising data from the interim analysis of its ongoing Phase 3 ASSURE study. The data were revealed in a recent press release, highlighting significant developments in the management of primary biliary cholangitis (PBC) using Livdelzi (seladelpar), a drug that holds the potential t...

Business Update

The Scientific Breakthrough and Market Dilemma Gilead Sciences? Livdelzi Surges Ahead in Medical Innovation

Published Sat, Nov 16 2024 3:40 AM UTC

FOSTER CITY, Calif. In a world constantly on the brink of medical breakthroughs, the recent announcement by Gilead Sciences, Inc. has caused ripples of optimism across the healthcare community. This is particularly true for patients battling primary biliary cholangitis (PBC), a chronic liver disease that for years has posed significant management challenges.Gilead Sciences...







Gilead Sciences Inc's Segments
U S    72.23 % of total Revenue
Europe    15.47 % of total Revenue
Rest of World    12.31 % of total Revenue
Total product sales    99.6 % of total Revenue
Total product sales U S    72.01 % of total Revenue
Total product sales Europe    15.29 % of total Revenue
Total product sales Rest of World    12.3 % of total Revenue
Total HIV    67.24 % of total Revenue
Total HIV U S    55.15 % of total Revenue
Total HIV Europe    7.55 % of total Revenue
Total HIV Rest of World    4.53 % of total Revenue
Biktarvy    46.02 % of total Revenue
Biktarvy U S    37.46 % of total Revenue
Biktarvy Europe    4.97 % of total Revenue
Biktarvy Rest of World    3.61 % of total Revenue
Descovy    7.77 % of total Revenue
Descovy U S    7.08 % of total Revenue
Descovy Europe    0.32 % of total Revenue
Descovy Rest of World    0.37 % of total Revenue
Genvoya    5.95 % of total Revenue
Genvoya U S    5.09 % of total Revenue
Genvoya Europe    0.58 % of total Revenue
Genvoya Rest of World    0.28 % of total Revenue
Odefsey    4.32 % of total Revenue
Odefsey U S    3.29 % of total Revenue
Odefsey Europe    0.91 % of total Revenue
Odefsey Rest of World    0.12 % of total Revenue
Symtuza - Revenue share    1.84 % of total Revenue
Symtuza - Revenue share U S    1.37 % of total Revenue
Symtuza - Revenue share Europe    0.44 % of total Revenue
Symtuza - Revenue share Rest of World    0.04 % of total Revenue
Other HIV    1.33 % of total Revenue
Other HIV U S    0.86 % of total Revenue
Other HIV Europe    0.34 % of total Revenue
Other HIV Rest of World    0.12 % of total Revenue
Total Liver Disease    9.72 % of total Revenue
Total Liver Disease U S    5.21 % of total Revenue
Total Liver Disease Europe    1.75 % of total Revenue
Total Liver Disease Rest of World    2.74 % of total Revenue
Sofosbuvir Velpatasvir    5.1 % of total Revenue
Sofosbuvir Velpatasvir U S    2.94 % of total Revenue
Sofosbuvir Velpatasvir Europe    0.89 % of total Revenue
Sofosbuvir Velpatasvir Rest of World    1.27 % of total Revenue
Vemlidy    3.07 % of total Revenue
Vemlidy U S    1.67 % of total Revenue
Vemlidy Europe    0.15 % of total Revenue
Vemlidy Rest of World    1.26 % of total Revenue
Other Liver Disease    1.54 % of total Revenue
Other Liver Disease U S    0.6 % of total Revenue
Other Liver Disease Europe    0.72 % of total Revenue
Other Liver Disease Rest of World    0.23 % of total Revenue
Veklury    9.17 % of total Revenue
Veklury U S    5.21 % of total Revenue
Veklury Europe    1.07 % of total Revenue
Veklury Rest of World    2.9 % of total Revenue
Total Oncology    10.82 % of total Revenue
Total Oncology U S    5.74 % of total Revenue
Total Oncology Europe    3.86 % of total Revenue
Total Oncology Rest of World    1.22 % of total Revenue
Total Cell Therapy    6.43 % of total Revenue
Total Cell Therapy U S    2.76 % of total Revenue
Total Cell Therapy Europe    2.8 % of total Revenue
Total Cell Therapy Rest of World    0.87 % of total Revenue
Tecartus    1.3 % of total Revenue
Tecartus U S    0.83 % of total Revenue
Tecartus Europe    0.38 % of total Revenue
Tecartus Rest of World    0.08 % of total Revenue
Yescarta    5.13 % of total Revenue
Yescarta U S    1.92 % of total Revenue
Yescarta Europe    2.41 % of total Revenue
Yescarta Rest of World    0.8 % of total Revenue
Trodelvy    4.4 % of total Revenue
Trodelvy U S    3 % of total Revenue
Trodelvy Europe    1.06 % of total Revenue
Trodelvy Rest of World    0.34 % of total Revenue
Total Other    2.66 % of total Revenue
Total Other U S    0.7 % of total Revenue
Total Other Europe    1.06 % of total Revenue
Total Other Rest of World    0.9 % of total Revenue
AmBisome    1.72 % of total Revenue
AmBisome U S    0.08 % of total Revenue
AmBisome Europe    0.94 % of total Revenue
AmBisome Rest of World    0.69 % of total Revenue
Other    0.94 % of total Revenue
Other U S    0.62 % of total Revenue
Other Europe    0.11 % of total Revenue
Other Rest of World    0.21 % of total Revenue
Royalty contract and other revenues    0.4 % of total Revenue
Royalty contract and other revenues U S    0.23 % of total Revenue
Royalty contract and other revenues Europe    0.17 % of total Revenue
Royalty contract and other revenues Rest of World    0.01 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com